ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates

Core Insights - ChromaDex (CDXC) reported quarterly earnings of $0.02 per share, exceeding the Zacks Consensus Estimate of $0.01 per share, and showing improvement from a loss of $0.01 per share a year ago, resulting in a 100% earnings surprise [1] - The company achieved revenues of $25.58 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 7.93% and increasing from $19.5 million year-over-year [2] - ChromaDex shares have increased approximately 150.4% year-to-date, significantly outperforming the S&P 500's gain of 21.9% [3] Earnings Outlook - The future performance of ChromaDex's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - Current consensus EPS estimate for the upcoming quarter is $0.02 on revenues of $26.1 million, and for the current fiscal year, it is $0.01 on revenues of $94.7 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ChromaDex belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8]